Skip to content
DataLookout
Menu

NCT07900555

Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 5 words
    • Study title expanded, about 2 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Clinical and Biochemical Disease Control
Timeframe: Up to 10 years after radiotherapy

Secondary (2)

Late Toxicity
Acute toxicity

Arms and interventions

Hypofractionated focal boost radiotherapyExperimental

Image-guided IMRT in 25 fractions: 2.9 Gy/fraction (72.5 Gy) to the MRI-defined tumour, 2.4 Gy/fraction (60 Gy) to the uninvolved prostate and seminal vesicles, and 2.0 Gy/fraction (50 Gy) to the elective pelvic lymph nodes, with a boost of 2.4 Gy/fraction (60 Gy) to involved lymph nodes in node-positive patients; androgen deprivation therapy planned for 18 months.

Radiation: Hypofractionated IMRT with focal simultaneous integrated boost and elective pelvic irradiation

Drugs: Androgen Deprivation Therapy (ADT)

Sites

1 site in 1 country

  • Haukeland University HospitalBergen, Vestland, Norway